MicroRNA‑589 serves as a tumor suppressor microRNA through directly targeting metastasis‑associated protein 2 in breast cancer

Chu,Jun

doi:10.3892/ol.2019.10548

MicroRNA‑589 serves as a tumor suppressor microRNA through directly targeting metastasis‑associated protein 2 in breast cancer

Authors:
- Jun Chu
View Affiliations

Affiliations: Department of Thyroid and Breast Surgery, Central Hospital of Zibo, Zibo, Shandong 255000, P.R. China
Published online on: June 28, 2019 https://doi.org/10.3892/ol.2019.10548
Pages: 2232-2239
Copyright: © Chu . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple‑negative breast cancer (TNBC) has a poorer outcome compared with that of other subtypes of breast cancer, and the discovery of dysregulated microRNA (miRNA) and their role in tumor progression has provided a new avenue for elucidating the mechanism involved in TNBC. Previous studies have revealed that aberrant expression of miRNA‑589 (miR‑589) was frequently observed in various types of cancer. However, the expression and function of miR‑589 in TNBC has not been well illustrated. In the present study, the expression level of miR‑589 was explored in TNBC tissues and TNBC cell lines by quantitative polymerase chain reaction (qPCR). The results revealed that the expression of miR‑589 was decreased in TNBC tissues and cell lines compared with that in normal tissues and breast cell lines. Furthermore, miR‑589 overexpression decreased the TNBC cell proliferation, migration and invasion, whereas miR‑589 silencing generated the opposite results in vitro. Bioinformatic algorithms predicted a direct target site for miR‑589 in the 3'‑untranslated region of metastasis‑associated protein 2 (MTA2), which was confirmed with a dual‑luciferase reporter assay and western blot analysis. Results of the qPCR and western blot analysis illustrated that miR‑589 negatively regulated MTA2 expression with regard to mRNA and protein levels in the TNBC cell lines. MTA2 silencing reversed the promotion function of miR‑589 inhibitor in the TNBC cell line. Finally, miR‑589 could inhibit the process of epithelial‑mesenchymal transition via MTA2. In summary, the present study revealed the biological function and molecular mechanism of miR‑589 in the progression of TNBC. MiR‑589 inhibition in the progression of TNBC may be a potential therapeutic target for TNBC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	DeSantis CE, Ma J, Goding Sauer A, Newman LA and Jemal A: Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 67:439–448. 2017. View Article : Google Scholar : PubMed/NCBI
3	Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
4	Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA: Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
5	Wahba HA and El-Hadaad HA: Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 12:106–116. 2015.PubMed/NCBI
6	Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 9:8522017. View Article : Google Scholar : PubMed/NCBI
7	Pasquinelli AE: MicroRNAs and their targets: Recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 13:271–282. 2012. View Article : Google Scholar : PubMed/NCBI
8	Christodoulatos GS and Dalamaga M: Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: Quo vadis? World J Clin Oncol. 5:71–81. 2014. View Article : Google Scholar : PubMed/NCBI
9	Lü L, Mao X, Shi P, He B, Xu K, Zhang S and Wang J: MicroRNAs in the prognosis of triple-negative breast cancer: A systematic review and meta-analysis. Medicine (Baltimore). 96:e70852017. View Article : Google Scholar : PubMed/NCBI
10	Piasecka D, Braun M, Kordek R, Sadej R and Romanska H: MicroRNAs in regulation of triple-negative breast cancer progression. J Cancer Res Clin Oncol. 144:1401–1411. 2018. View Article : Google Scholar : PubMed/NCBI
11	Xu M, Wang Y, He HT and Yang Q: MiR-589-5p is a potential prognostic marker of hepatocellular carcinoma and regulates tumor cell growth by targeting MIG-6. Neoplasma. 65:753–761. 2018. View Article : Google Scholar : PubMed/NCBI
12	Cesarini V, Silvestris DA, Tassinari V, Tomaselli S, Alon S, Eisenberg E, Locatelli F and Gallo A: ADAR2/miR-589-3p axis controls glioblastoma cell migration/invasion. Nucleic Acids Res. 46:2045–2059. 2018. View Article : Google Scholar : PubMed/NCBI
13	Liu C, Lv D, Li M, Zhang X, Sun G, Bai Y and Chang D: Hypermethylation of miRNA-589 promoter leads to upregulation of HDAC5 which promotes malignancy in non-small cell lung cancer. Int J Oncol. 50:2079–2090. 2017. View Article : Google Scholar : PubMed/NCBI
14	Zhang X, Jiang P, Shuai L, Chen K, Li Z, Zhang Y, Jiang Y and Li X: miR-589-5p inhibits MAP3K8 and suppresses CD90⁺ cancer stem cells in hepatocellular carcinoma. J Exp Clin Cancer Res. 35:1762016. View Article : Google Scholar : PubMed/NCBI
15	Zhang F, Li K, Pan M, Li W, Wu J, Li M, Zhao L and Wang H: miR-589 promotes gastric cancer aggressiveness by a LIFR-PI3K/AKT-c-Jun regulatory feedback loop. J Exp Clin Cancer Res. 37:1522018. View Article : Google Scholar : PubMed/NCBI
16	Patil Okaly GV, Panwar D, Lingappa KB, Kumari P, Anand A, Kumar P, Chikkalingaiah MH and Kumar RV: FISH and HER2/neu equivocal immunohistochemistry in breast carcinoma. Indian J Cancer. 56:119–123. 2019. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. Elife. 4:2015. View Article : Google Scholar
19	Fu J, Qin L, He T, Qin J, Hong J, Wong J, Liao L and Xu J: The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis. Cell Res. 21:275–289. 2011. View Article : Google Scholar : PubMed/NCBI
20	Long J, Jiang C, Liu B, Dai Q, Hua R, Chen C, Zhang B and Li H: Maintenance of stemness by miR-589-5p in hepatocellular carcinoma cells promotes chemoresistance via STAT3 signaling. Cancer Lett. 423:113–126. 2018. View Article : Google Scholar : PubMed/NCBI
21	Kumar R, Wang RA and Bagheri-Yarmand R: Emerging roles of MTA family members in human cancers. Semin Oncol 30 (5 Suppl). S30–S37. 2003. View Article : Google Scholar
22	Covington KR and Fuqua SA: Role of MTA2 in human cancer. Cancer Metastasis Rev. 33:921–928. 2014. View Article : Google Scholar : PubMed/NCBI
23	Covington KR, Brusco L, Barone I, Tsimelzon A, Selever J, Corona-Rodriguez A, Brown P, Kumar R, Hilsenbeck SG and Fuqua SA: Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. Breast Cancer Res Treat. 141:375–384. 2013. View Article : Google Scholar : PubMed/NCBI